Dai Lifei, Xiang Junlian, Liu Xiaoli, Wen Xiaoyan, Tan Lin, Zhang Jiali
School of Basic Medical Sciences & School of Nursing, Chengdu University, Chengdu, China.
Department of Urology, Deyang People's Hospital, Deyang, China.
Front Surg. 2025 Jun 19;12:1603311. doi: 10.3389/fsurg.2025.1603311. eCollection 2025.
Ureteroscopic lithotripsy (URSL) is the preferred treatment for urinary tract stones, with urosepsis being its most severe postoperative complication. Although previous studies have investigated risk factors for urosepsis after URSL, significant variations exist in reported risk factors and their associated odds ratios (), leading to inconsistent findings across studies. This systematic review and meta-analysis investigated the risk factors for urosepsis after URSL, aiming to establish a scientific foundation for early clinical identification and to reduce the incidence and mortality of this complication.
Case-control and cohort studies on factors influencing urosepsis after URSL were systematically retrieved from major public medical databases, including PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data, and Chinese Science and Technology Journal Database, up to January 31, 2025. Two researchers independently conducted literature screening, data extraction, quality assessment, and meta-analysis using Stata versions 15.1 and 18.0.
A total of 26 studies were included in this analysis, comprising 12,394 patients, of whom 861 patients developed urosepsis. The influencing factors for urosepsis included stone size[OR = 3.10, 95% CI (1.20,8.00), = 0.002], number of stones [OR = 7.59, 95% confidence interval (CI): 3.82, 15.08; < 0.001], history of urinary tract infection (OR = 5.96, 95% CI: 4.12, 8.60; < 0.001), positive urine culture (OR = 4.95, 95% CI: 3.90, 6.28; < 0.001), positive urinary nitrite (OR = 7.68, 95% CI: 1.03, 52.27; = 0.047], C-reactive protein (OR = 4.3, 95% CI: 1.06, 17.49; = 0.042), diabetes (OR = 3.60, 95% CI: 3.11, 4.16; < 0.001), operation time (OR = 1.09, 95% CI: 1.07, 1.11; < 0.001), and stent placement (OR = 3.71, 95% CI: 1.94, 7.09; < 0.001].
Urosepsis following URSL is associated with a high mortality rate and significantly threatens patient safety and quality of life. Early identification of the factors influencing urosepsis is crucial to reduce its incidence and improve patient outcomes.
PROSPERO CRD42025641787.
输尿管镜碎石术(URSL)是治疗尿路结石的首选方法,尿脓毒症是其最严重的术后并发症。尽管先前的研究已经调查了URSL术后尿脓毒症的危险因素,但报告的危险因素及其相关比值比(OR)存在显著差异,导致各研究结果不一致。本系统评价和荟萃分析调查了URSL术后尿脓毒症的危险因素,旨在为早期临床识别建立科学依据,并降低该并发症的发生率和死亡率。
从主要公共医学数据库系统检索关于影响URSL术后尿脓毒症因素的病例对照研究和队列研究,包括PubMed、Web of Science、Embase、Cochrane图书馆、中国知网(CNKI)、万方数据和中国科技期刊数据库,截至2025年1月31日。两名研究人员独立进行文献筛选、数据提取、质量评估,并使用Stata 15.1版和18.0版进行荟萃分析。
本分析共纳入26项研究,包括12394例患者,其中861例发生尿脓毒症。尿脓毒症的影响因素包括结石大小[OR = 3.10,95%置信区间(CI):(1.20,8.00),P = 0.002]、结石数量[OR = 7.59,95%置信区间(CI):3.82,15.08;P < 0.001]、尿路感染史(OR = 5.96,95% CI:4.12,8.60;P < 0.001)、尿培养阳性(OR = 4.95,95% CI:3.90,6.28;P < 0.001)、尿亚硝酸盐阳性(OR = 7.68,95% CI:1.03,52.27;P = 0.047)、C反应蛋白(OR = 4.3,95% CI:1.06,17.49;P = 0.042)、糖尿病(OR = 3.60,95% CI:3.11,4.16;P < 0.001)、手术时间(OR = 1.09,95% CI:1.07,1.11;P < 0.001)和支架置入(OR = 3.71,95% CI:1.94,7.09;P < 0.001)。
URSL术后尿脓毒症死亡率高,严重威胁患者安全和生活质量。早期识别影响尿脓毒症的因素对于降低其发生率和改善患者预后至关重要。
PROSPERO CRD42025641787。